biopharma

4+ articles

AI Anthropic Boston Bristol Myers Squibb Elon Musk

Anthropic's Bold Move: Acquiring Stealth AI Innovator Coefficient Bio for $400M

Anthropic, the trailblazer in AI, has expanded its horizons by acquiring Coefficient Bio—a stealth startup backed by Dimension— for over $400 million. Known for developing cutting-edge AI models for biological research, Coefficient Bio is set to enhance Anthropic's capabilities in the life sciences sector.

Apr 3

Anthropic's Bold Move: Acquiring Stealth AI Innovator Coefficient Bio for $400M

Boston's Biotech Sector Stumbles: Ph.D.s Struggle Amid Economic Woes

As Boston's once-thriving biotech industry faces a downturn, Ph.D. graduates are struggling to find employment due to reduced venture capital and government funding. This economic shift has resulted in layoffs and high lab vacancy rates. The future looks challenging with continued losses and state responses aiming for recovery.

Dec 30

Boston's Biotech Sector Stumbles: Ph.D.s Struggle Amid Economic Woes

Elon Musk's Ally Antonio Gracias Eyes Major Role in Psychedelic Medicine with Lykos Therapeutics Takeover

Antonio Gracias, a close ally of Elon Musk, is in the spotlight with a bid to take over Lykos Therapeutics—a move potentially worth $100 million. Backed by major investors including Sir Christopher Hohn, the acquisition aims to reshape the future of MDMA-assisted therapies, bringing management shakeups and sparking debates on drug policy and approval processes. This pivotal development highlights the increasing financial interest in the psychedelic medicine industry.

Aug 28

Elon Musk's Ally Antonio Gracias Eyes Major Role in Psychedelic Medicine with Lykos Therapeutics Takeover

AI: The Sleeping Giant in Biopharma

AI is poised to revolutionize the biopharmaceutical industry, promising to reduce drug development time by up to 10X and improve clinical trial efficiency. However, the road to widespread adoption is slower than anticipated due to regulatory complexities and the intricate nature of the pharmaceutical landscape.

Jan 10